


AMENDMENTS TO THE SPECIFICATION

The paragraph beginning on page 16, line 7, is being amended as follows:

5. The compound according to 1 represented by the formula (I-d):



wherein R^{3d} and R^{16d} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) $R^dC(=O)-O-$, wherein R^d represents
 - a) a hydrogen atom,
 - b) a C_1 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a

substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C_6 to C_{14} aryloxy group which may have a substituent or

k) a 5-membered to 14-membered heteroaryloxy group which may have a substituent or

6) $R^{dn1}R^{dn2}N-CO-O-$, wherein R^{dn1} and R^{dn2} , the same or different, independently represent

a) a hydrogen atom,

b) a C_1 to C_{22} alkyl group which may have a substituent,

c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,

d) a C_6 to C_{14} aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_3 to C_{14} cycloalkyl group which may have a substituent,

i) a 3-membered to 14-membered non-aromatic

heterocyclic group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{dn1} and R^{dn2} together in combination with the nitrogen atom to which R^{dn1} and R^{dn2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent and

R^{7d} and R^{21d} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) $R^dC(=O)-O-$, wherein R^d is the same as defined above,
- 6) $R^{dn1}R^{dn2}N-CO-O-$, wherein R^{dn1} and R^{dn2} are the same as defined above,
- 7) $R^{dn1}R^{dn2}N-SO_2-O-$, wherein R^{dn1} and R^{dn2} are the same as defined above,
- 8) $R^{dn1}R^{dn2}N-CS-O-$, wherein R^{dn1} and R^{dn2} are the same as defined above,
- 9) $R^{dn4}-SO_2-O-$, wherein R^{dn4} represents

- a) a C_1 to C_{22} alkyl group which may have a substituent,
- b) a C_6 to C_{14} aryl group which may have a substituent,
- c) a C_1 to C_{22} alkoxy group which may have a substituent,
- d) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- e) a C_6 to C_{14} aryloxy group which may have a

substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

10) (R^{dn5}O)₂PO-O-, wherein R^{dn5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C₇ to C₂₂ aralkyl group which may have a substituent or


f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) (R^{dn1}R^{dn2}N)₂PO-O-, wherein R^{dn1} and R^{dn2} are the same as defined above or

12) (R^{dn1}R^{dn2}N)(R^{dn5}O)PO-O-, wherein R^{dn1}, R^{dn2} and R^{dn3} R^{dn5} are the same as defined above; a pharmacologically acceptable salt thereof, or a hydrate of those;

The paragraph beginning on page 20, line 18, is being amended as follows:

7. The compound according to 5 represented by the formula (I-e) :



wherein R^{3e} , R^{16e} and R^{21e} , the same or different, independently represent

- 1) a hydroxyl group,
- 2) a C_1 to C_{22} alkoxy group which may have a substituent,
- 3) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 4) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 5) an aliphatic C_2 to C_6 acyl group which may have a substituent

or

6) $R^{eN1}R^{eN2}N-CO-O-$, wherein R^{eN1} and R^{eN2} independently represent

- a) a hydrogen atom or
- b) a C_1 to C_6 alkyl group which may have a substituent

and

R^{7e} represents $R^e-C(=Y^e)-O-$, wherein Y^e represents an oxygen atom or sulfur atom, and R^e , ~~the same or different,~~ represents

- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,
- c) a C_6 to C_{14} aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which


may have a substituent,

e) a C₇ to C₁₀ aralkyl group which may have a substituent,

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_e represents

i) -CHR^{eN4}-,

ii) -NR^{eN5}-,

iii) -O-,

iv) -S-,

v) -SO- or

vi) -SO₂-,

R^{eN1} represents

i) a hydrogen atom or

ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN2} represents

i) a hydrogen atom or

ii) a C₁ to C₆ alkyl group which may have a substituent,

R^{eN3} and R^{eN4} , the same or different, independently represent

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- iv) a C_6 to C_{14} aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C_7 to C_{10} aralkyl group which may have a substituent,
- vii) a C_3 to C_8 cycloalkyl group which may have a substituent,
- viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) $-NR^{eN6}R^{eN7}$, wherein R^{eN6} and R^{eN7} , the same or different, independently represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN4} together in combination with the carbon atom to which R^{eN3} and R^{eN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent and

R^{eN5} represents

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- iv) a C_6 to C_{14} aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C_7 to C_{10} aralkyl group which may have a substituent,
- vii) a C_3 to C_8 cycloalkyl group which may have a substituent,
- viii) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
- xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN3} and R^{eN5} together in combination with the nitrogen atom to which R^{eN3} and R^{eN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, B)

X_e , n , R^{eN3} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN2} independently represent a 5-membered to 14-membered non-aromatic heterocyclic

group formed by R^{eN1} and R^{eN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,


C)

X_e , n , R^{eN2} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN1} and R^{eN2} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN1} and R^{eN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_e , n , R^{eN1} , R^{eN4} and R^{eN5} independently represent the same group as defined above, and R^{eN2} and R^{eN3} independently represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{eN2} and R^{eN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{eN8} and R^{eN9} , the same or different, independently represent

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) a C_6 to C_{14} aryl group which may have a

substituent,


iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,

v) a C₇ to C₁₀ aralkyl group which may have a substituent or

vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; a pharmacologically acceptable salt thereof, or a hydrate of those;


The paragraph beginning on page 75, line 17, is being amended as follows:

The compound of the formula (I) can be produced by chemical modification of, a key compound such as a 6-deoxy 11107 compound or a 6-deoxy compound using a conventional method as follows. The 6-deoxy 11107 compound is obtained by culturing, under aerobic conditions, a strain belonging to the genus *Streptomyces*, which is capable of producing a 6-deoxy 11107 compound as a physiologically active substance of the formula (I), wherein [1] W is




R³ and R²¹ are a hydroxyl group, R⁷ is an acetoxy group, and R¹⁶, R¹⁷, R²⁰ and R^{21'} are a hydrogen atom (6-deoxy 11107B),

[3] W is




R^3 , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom (6-deoxy 11107D),

[7] W is



R^3 , R^{17} , R^{16} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{20} and $R^{21'}$ are a hydrogen atom, and collecting the compound from the cells and culture solution; and the 6-deoxy compound is obtained by biologically converting a compound of the formula (I), wherein

[1] W is




R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16} , R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom (hereinafter referred to as "6-deoxy 11107B") to a compound of the formula (I), wherein

[2] W is




R^3 and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{16} , R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom,

[4] W is




R^{21} and $R^{21'}$ form an oxo group together with carbon to which R^{21} and $R^{21'}$ are bonded, R^3 , R^{16} and R^{20} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} is a hydrogen atom,

[5] W is




R^3 , R^{16} , R^{20} and R^{21} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and $R^{21'}$ are a hydrogen atom,

[6] W is



R^3 , R^7 , R^{16} and R^{21} are a hydroxyl group, and R^{17} , R^{20} and $R^{21'}$ are a hydrogen atom or



[8] W is



R^{21} and $R^{21'}$ form an oxo group together with carbon to which R^{21} and $R^{21'}$ are bonded, R^3 and R^{16} are a hydroxyl group, R^7 is an acetoxy group, and R^{17} and R^{20} are a hydrogen atom; and by chemically modifying the key compound using a conventional method in an appropriate manner.

The paragraph beginning on page 220, line 10, is being amended as follows:

(2) (8E,12E,14E) -3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7- (N-methyl-N- (2- (piperidin-1-yl) ethyl) carbamoyloxy) -18,19-epoxytricos-8,12,14-trien-11-olide (compound 53)



The paragraph beginning on page 230, line 6, is being amended as follows:

(2) (8E,12E,14E)-3,16,21-trihydroxy-6,10,12,16,20-pentamethyl-7-(N-methyl-N-(2-(N'-methylamino)cyclohexyl)carbamoyloxy)-18,19-epoxytricos-8,12,14-trien-11-olide (compound 57)

